Biosimilars

Global Market Trajectory & Analytics

MCP-6201

EXECUTIVE ENGAGEMENTS

POOL

10129
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1213
Interactions with Platform & by Email

PARTICIPANTS

304
Unique # Participated

VALIDATIONS

96
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

74

PAGES

150

EDITION

18

PRICE

USD 5600

CODE

MCP-6201


COMPETITIVE METRICS

COMPANY

D S N T

% *

3SBio, Inc.

Actavis UK Ltd

Actavis, Inc.

Allergan PLC

Alteogen, Inc.

Alvogen

Alvotech

Amgen, Inc.

Apotex, Inc.

Aprogen

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Biosimilars estimated at US$7.5 Billion in the year 2020, is projected to reach a revised size of US$45.5 Billion by 2027, growing at a CAGR of 29.3% over the analysis period 2020-2027. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is projected to record a 28.9% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Recombinant Glycosylated Proteins segment is readjusted to a revised 33.4% CAGR for the next 7-year period.
The Biosimilars market in the U.S. is estimated at US$2.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2027 trailing a CAGR of 28.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.1% and 25.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 20.7% CAGR.
In the global Recombinant Peptides segment, USA, Canada, Japan, China and Europe will drive the 23.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$6.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.4 Billion by the year 2027.

SELECT PLAYERS

Allergan Plc; Amgen Inc.; Biocon Ltd.; Biopartners GmbH; Boehringer Ingelheim International GmbH; Celltrion Inc.; Dr. Reddy`s Laboratories Ltd.; Eli Lilly and Company; Fresenius Kabi; Intas Pharmaceuticals Ltd.; Mylan NV; Pfizer Inc.; Samsung Bioepis Co. Ltd.; Sandoz International GmbH; STADA Arzneimittel AG; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Product Type (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides) » Disease (Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases, Other Diseases)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Biosimilars: An Introductory Prelude
Recent Market Activity
World Healthcare Sector Gears Up for Biosimilar Wave
Biosimilars Offer Great Promise Despite Challenges
The US & Europe Drive Momentum in Worldwide Biosimilars Sales
Emerging Markets also Offer Robust Growth Opportunities
R&D Funding: Crucial for Future Expansion of Biosimilars Market
Prevailing Economic Scenario Favors Funding Pattern
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Allergan Plc (Ireland)
Amgen, Inc. (USA)
Biocon Ltd. (India)
Biopartners GmbH (Switzerland)
Boehringer Ingelheim International GmbH (Germany)
Celltrion, Inc. (South Korea)
Dr. Reddy's Laboratories Ltd. (India)
Eli Lilly and Company (USA)
Fresenius Kabi (Germany)
Intas Pharmaceuticals Ltd. (India)
Mylan N.V. (USA)
Pfizer, Inc. (USA)
Samsung Bioepis Co., Ltd. (Korea)
Sandoz International GmbH (Germany)
STADA Arzneimittel AG (Germany)
Teva Pharmaceutical Industries Ltd. (Israel)
3. MARKET TRENDS & DRIVERS
Slew of Product Approvals Scale Up Market Revenues
Biosimilar Approvals in Europe (as of H1 2018)
Biosimilar Approvals in the US (as of H1 2018)
Pipeline Biosimilar Products in the US (as of H1 2018)
Biosimilar Approvals in South Korea (as of H1 2018)
Patent Expiry of Major Biopharmaceutical Drugs Leads Way for Biosimilars
Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
Cost Containment Measures Put Focus on Biosimilars
High Cost of Biologics - Favorable for Biosimilars
Efforts to Push Up Biosimilar Adoption Aid Market Expansion
Increasing Share of Biotech Drugs to Drive Biosimilars Market
Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
Specific Guidelines for Biosimilars in Various Countries with Year of Publication
Biosimilars Regulatory Agencies in Select Regional Markets
Improvement in Nomenclature & Interchangeability Enhance Appeal & Image of Biosimilars
Human Insulin Biosimilars Eye Potential Opportunities
Monoclonal Antibodies - A Key Segment for Biosimilars
Approved Monoclonal Antibodies (2014-2017)
Rituximab Biosimilars to Proliferate the Market
Growing Incidence of Chronic Diseases & Ageing Population Widen Prospects for Biosimilars
Growing Biosimilars Market - A Clear Advantage for Bioseparation Technologies
Growth Restraints
Lack of Uniform Regulations
High Lead-time
High Manufacturing Costs
Difficulties in Delivery & Commercialization
Automatic Substitution
Biobetters: A Potential Industry Challenge
Other Impediments to Market Acceptance
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Recombinant Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Recombinant Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Blood Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Blood Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Chronic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Chronic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
USA Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Canada Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Japan Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
CHINA
China Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
China Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for Biosimilars by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Europe Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
France Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Germany Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Italy Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
UK Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
Rest of World Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
Total Companies Profiled: 46

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com